Table 2 Study endpoints in diabetics vs. overall study population, and in incretin-users vs. never-incretin-users
Non-diabetic patients | Diabetic patients | p | PSM-diabetic never incretinusers | PSM-diabetic current incretinusers | p | |
|---|---|---|---|---|---|---|
N | 796 | 292 | 67 | 67 | ||
All cause deaths | 9 (1.1%) | 6 (2.2%) | 0.05 | 3 (4.5%) | 3 (4.5%) | / |
Cardiac deaths | 39 (0.5%) | 5 (1.6%) | 0.045 | 3 (4.5%) | 2 (3.0%) | / |
MACE | 47 (5.9%) | 38 (12.9%) | 0.001 | 9 (12.9%) | 5 (7.4%) | 0.04 |